Real-World Evidence Prediction of a Phase IV Oncology Trial: Comparative Degarelix vs Leuprolide Safety.
Journal
JNCI cancer spectrum
ISSN: 2515-5091
Titre abrégé: JNCI Cancer Spectr
Pays: England
ID NLM: 101721827
Informations de publication
Date de publication:
10 Aug 2022
10 Aug 2022
Historique:
received:
17
03
2022
revised:
06
05
2022
accepted:
09
05
2022
entrez:
10
8
2022
pubmed:
11
8
2022
medline:
11
8
2022
Statut:
aheadofprint
Résumé
Medical and regulatory communities are increasingly interested in the utility of real-world evidence (RWE) for answering questions pertaining to drug safety and effectiveness but concerns about validity remain. A principled approach to conducting RWE studies may alleviate concerns and increase confidence in findings. This study sought to predict the findings from the PRONOUNCE trial using a principled approach to generating RWE. This propensity-score (PS) matched observational cohort study utilized 3 claims databases to compare the occurrence of major adverse cardiovascular events (MACE) among initiators of degarelix vs. leuprolide. Patients were included if they had history of prostate cancer and atherosclerotic cardiovascular disease. Subjects were excluded if they didn't have continuous database enrollment in the year prior to treatment initiation, were exposed to androgen deprivation therapy or experienced an acute cardiovascular event within 30 days prior to treatment initiation, or had a history or risk factors of QT prolongation. There were 12,448 leuprolide and 1,969 degarelix study-eligible patients before matching, with 1,887 in each arm after PS-matching. The results for MACE comparing degarelix to leuprolide in the observational analysis (hazard ratio= 1.35; 95% confidence interval = 0.94-1.93) was consistent with the subsequently released PRONOUNCE result (hazard ratio = 1.28; 95% confidence interval = 0.59-2.79). This study successfully predicted the result of a comparative cardiovascular safety trial in the oncology setting. Although the findings are encouraging, limitations of measuring cancer stage and tumor progression are representative of challenges in attempting to generalize whether claims-based RWE can be used as actionable evidence.
Sections du résumé
BACKGROUND
BACKGROUND
Medical and regulatory communities are increasingly interested in the utility of real-world evidence (RWE) for answering questions pertaining to drug safety and effectiveness but concerns about validity remain. A principled approach to conducting RWE studies may alleviate concerns and increase confidence in findings. This study sought to predict the findings from the PRONOUNCE trial using a principled approach to generating RWE.
METHODS
METHODS
This propensity-score (PS) matched observational cohort study utilized 3 claims databases to compare the occurrence of major adverse cardiovascular events (MACE) among initiators of degarelix vs. leuprolide. Patients were included if they had history of prostate cancer and atherosclerotic cardiovascular disease. Subjects were excluded if they didn't have continuous database enrollment in the year prior to treatment initiation, were exposed to androgen deprivation therapy or experienced an acute cardiovascular event within 30 days prior to treatment initiation, or had a history or risk factors of QT prolongation.
RESULTS
RESULTS
There were 12,448 leuprolide and 1,969 degarelix study-eligible patients before matching, with 1,887 in each arm after PS-matching. The results for MACE comparing degarelix to leuprolide in the observational analysis (hazard ratio= 1.35; 95% confidence interval = 0.94-1.93) was consistent with the subsequently released PRONOUNCE result (hazard ratio = 1.28; 95% confidence interval = 0.59-2.79).
CONCLUSIONS
CONCLUSIONS
This study successfully predicted the result of a comparative cardiovascular safety trial in the oncology setting. Although the findings are encouraging, limitations of measuring cancer stage and tumor progression are representative of challenges in attempting to generalize whether claims-based RWE can be used as actionable evidence.
Identifiants
pubmed: 35947646
pii: 6659860
doi: 10.1093/jncics/pkac049
pmc: PMC9403105
pii:
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL141505
Pays : United States
Informations de copyright
© The Author(s) 2022. Published by Oxford University Press.
Références
J Urol. 2019 Sep;202(3):518-524
pubmed: 31009286
Prostate Cancer Prostatic Dis. 2019 Mar;22(1):24-38
pubmed: 30131604
Cancer. 2012 Jul 1;118(13):3397-406
pubmed: 22072494
Nat Rev Rheumatol. 2015 Jul;11(7):437-41
pubmed: 25800216
Eur Urol. 2012 Jun;61(6):1119-28
pubmed: 22336376
JAMA Intern Med. 2018 Jan 1;178(1):55-63
pubmed: 29159410
Clin Pharmacol Ther. 2019 Apr;105(4):867-877
pubmed: 30636285
Clin Pharmacol Ther. 2007 Aug;82(2):143-56
pubmed: 17554243
N Engl J Med. 2009 Jun 11;360(24):2516-27
pubmed: 19516032
BJU Int. 2008 Dec;102(11):1531-8
pubmed: 19035858
Eur Urol. 2014 Mar;65(3):565-73
pubmed: 24210090
Basic Clin Pharmacol Toxicol. 2006 Mar;98(3):311-3
pubmed: 16611207
Oncology (Williston Park). 2009 Jun;23(7):626-30
pubmed: 19626830
N Engl J Med. 2016 Dec 8;375(23):2293-2297
pubmed: 27959688
JACC CardioOncol. 2020 Mar 17;2(1):70-81
pubmed: 34396210
Clin Pharmacol Ther. 2016 Mar;99(3):325-32
pubmed: 26690726
JAMA Netw Open. 2021 Oct 1;4(10):e2130587
pubmed: 34677594
Pharmacoepidemiol Drug Saf. 2013 Jan;22(1):1-6
pubmed: 23023988
Epidemiology. 2018 Sep;29(5):e45-e47
pubmed: 29912013
Int J Clin Pract. 2011 May;65(5):559-66
pubmed: 21342376
Stat Med. 2014 May 10;33(10):1685-99
pubmed: 24323618
Endocr Rev. 2021 Sep 28;42(5):658-690
pubmed: 33710268
Circulation. 2021 Oct 19;144(16):1295-1307
pubmed: 34459214
J Natl Cancer Inst. 2007 Oct 17;99(20):1516-24
pubmed: 17925537
Clin Pharmacol Ther. 2020 Apr;107(4):817-826
pubmed: 31541454
Pharmacoepidemiol Drug Saf. 2020 Nov;29(11):1382-1392
pubmed: 32964514
Arthritis Rheumatol. 2017 Jun;69(6):1154-1164
pubmed: 28245350
Ann Intern Med. 2017 Aug 15;167(4):268-274
pubmed: 28693043
N Engl J Med. 2015 Aug 20;373(8):737-46
pubmed: 26244877
J Gen Intern Med. 2011 May;26(5):546-50
pubmed: 21203857
Lancet. 2016 Mar 19;387(10024):1163-77
pubmed: 26719232
Circulation. 2021 Mar 9;143(10):1002-1013
pubmed: 33327727
J Clin Oncol. 2006 Sep 20;24(27):4448-56
pubmed: 16983113